POTS (postural orthostatic tachycardia syndrome) is not a rare disease by the official definition. An estimated 1 to 3 million people in the United States have the condition, far exceeding the threshold of fewer than 200,000 cases that the FDA uses to classify a disease as rare. Despite those numbers, POTS has historically been underdiagnosed and poorly recognized, which gave many people the impression it was uncommon.
Why POTS Seems Rarer Than It Is
The gap between how many people have POTS and how many people get diagnosed is enormous. Patients report seeing an average of seven physicians before receiving a correct diagnosis, with an average delay of nearly five years from when symptoms first appear. A multinational chart audit found that roughly 80% of POTS patients received at least one incorrect diagnosis before eventually being identified, and 25% waited over a year even after the right testing began. Most patients underwent five to eight tests before the diagnosis was confirmed.
That diagnostic journey makes POTS feel rare to patients and doctors alike. If a general practitioner has never diagnosed it, they may assume it barely exists. In reality, the condition simply falls through the cracks of a medical system that hasn’t historically trained most physicians to recognize it.
How Common POTS Actually Is
Before the COVID-19 pandemic, the incidence rate of POTS was estimated at about 1.42 cases per million people per year. After the pandemic, that number jumped to roughly 22.66 cases per million, a more than fifteenfold increase. Current estimates suggest POTS affects somewhere around 0.2% of the population, with some reports citing rates as high as 170 per 100,000 people.
The pandemic played a significant role in these rising numbers. Clinicians specializing in autonomic disorders have reported that up to 80% of long COVID patients meet the diagnostic criteria for POTS. With at least 65 million people worldwide estimated to have long COVID, even a fraction developing POTS translates to a massive wave of new cases.
Who Gets POTS
POTS can affect anyone, but the pattern is strikingly consistent: 75% to 80% of patients are female, and most are between 15 and 25 years old at the time of diagnosis. That demographic profile, young women with symptoms like dizziness, fatigue, and a racing heart, has historically contributed to dismissal by physicians who attributed the complaints to anxiety or deconditioning.
The condition is defined by a specific measurable change. When a person with POTS stands up, their heart rate increases by more than 30 beats per minute (or exceeds 120 beats per minute) within 10 minutes. For adolescents, the threshold is higher: an increase of at least 40 beats per minute. This isn’t a subjective diagnosis. It shows up clearly on a tilt table test or even a simple standing test with a heart rate monitor.
Conditions That Overlap With POTS
POTS rarely travels alone. In a large survey of nearly 5,000 POTS patients, 25% also had Ehlers-Danlos syndrome, a connective tissue disorder that causes joint hypermobility and fragile skin. Another 9% had mast cell activation syndrome, a condition where the immune system overreacts and triggers flushing, hives, or gastrointestinal problems. These overlapping conditions can complicate the diagnostic picture further, since each one may send a patient to a different specialist who only sees part of the problem.
Post-COVID POTS vs. Pre-COVID POTS
One reasonable question is whether the POTS triggered by COVID-19 is fundamentally different from the condition that existed before the pandemic. So far, the answer appears to be no, at least not in clinically meaningful ways. A comparative analysis found that post-COVID POTS patients tended to be somewhat older and had fewer pre-existing conditions, but the diagnostic process, management strategies, and treatment patterns looked essentially the same. In other words, POTS is POTS regardless of what triggered it.
What the pandemic did change was visibility. The sheer volume of new cases forced broader medical attention to a condition that autonomic specialists had been treating for decades. More physicians now recognize the name, even if many still lack confidence in diagnosing or managing it. For patients who spent years being told nothing was wrong, that shift in awareness has been significant.